Effects of astragalus membranaceus parenteral solution combined with recombinant human erythropietin on erythrocyte immunity function in patients with hemodialysis
10.3760/cma.j.issn.1673-4904.2010.22.009
- VernacularTitle:黄芪注射液联合重组人促红细胞生成素对血液透析患者红细胞免疫功能的影响
- Author:
Xuebo CHEN
;
Yuwen HU
;
Guangyu WU
- Publication Type:Journal Article
- Keywords:
Astrngahis membranaceus;
Kidney failure,chronic;
Recombinant human erythropoietin;
Renal dialysis;
Erythrocyte immune function
- From:
Chinese Journal of Postgraduates of Medicine
2010;33(22):24-26
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of astragalus membranaceus parenteral solution combined with recombinant human erythropietin (rHuEPO) on erythrocyte immunity function in patients with hemodialysis. Methods Fifty-one patients of chronic renal failure(CRF) with hemodialysis were divided into 2 groups randomly according to whether treated with astragalus membranaceus parenteral solution or not(therapeutic group, was 26 cases and control group was 25 cases). IgG, IgA, IgM, RBC-C3b,RR,RBC-ICR, erythrocyte percentage of CD35 positive and SOD was measured before treatment and 8 weeks after treatment. Results After 8 weeks' treatment, IgG,IgA,IgM levels in therapeutic group and IgG,IgA levels in control group were higher than those before treatment(P < 0.01 ). IgM [ (2.03±0.73 ) g/L ] was higher than that in control group (P< 0.05). RBC-C3B,RR, erythrocyte percentage of CD35 positive and SOD were higher and RBC-ICR was lower than those before treatment in two groups (P < 0.05 ) ;compared with that in control group, RBC-C3b, RR was higher [(10.85±2.31 )% ] and RBC-ICR was lower [(5.34±1.91 )% ] (P < 0.05 ).Conclusion Astragalus membranaceus parenteral solution combined with rHuEPO is superior to improve CRF patients' levels of immune globulin and erythrecyte immunity function.
